Selection of an M184V mutation in the cerebrospinal fluid of a treatment-naive HIV-infected individual starting darunavir-based therapy.
نویسندگان
چکیده
Here, we describe a newly diagnosed HIV-1-infected patient, in whom shortly after the initiation of a darunavir-based regimen, the HIV-1 virus exclusively mutated in the cerebrospinal fluid (CSF), leading to an increase in CSF HIV-1 RNA load and neurological complaints.
منابع مشابه
Orogastric administration of crushed darunavir tablets for a critically ill patient.
When HIV-positive patients are critically ill and unable to take medications orally, administration of highly active antiretroviral therapy (HAART) becomes challenging. The foremost issue is the lack of parenteral formulations and oral suspensions. Only limited clinical evidence directly addresses the conversion of antiretroviral drugs from the oral to the enteral route. Interruption of HAART i...
متن کاملHigh rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.
BACKGROUND The introduction of 2 or 3 fully active drugs in human immunodeficiency virus (HIV)-infected patients receiving failing antiretroviral therapy is a key determinant of subsequent treatment efficacy. The aim of this study was to assess the safety and efficacy of a regimen containing raltegravir, etravirine, and darunavir/ritonavir for treatment-experienced patients infected with multid...
متن کاملA case of cerebrospinal fluid viral escape on a dual antiretroviral regimen: worth the risk?
TO THE EDITOR—Among human immunodeficiency virus (HIV)-infected patients on antiretroviral therapy (ART), incomplete viral suppression in cerebrospinal fluid (CSF) may occur even with undetectable plasma viremia [1–4]. Treatment simplification with “less-drug regimens” may favor adherence and reduce toxicity, but raises concerns on lower central nervous system (CNS) drug penetration and subsequ...
متن کاملCerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir/ritonavir monotherapy
Darunavir/ritonavir monotherapy maintains HIV suppression in most patients who have achieved an undetectable viral load on combination antiretroviral treatment, and is increasingly used in the clinic. However, concerns have been raised about the effectiveness of ritonavir-boosted protease inhibitor (PI/r) monotherapy in the prevention of HIV replication in the central nervous system (CNS). Here...
متن کاملCerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control.
BACKGROUND Despite the efficacy of highly active antiretroviral treatment (HAART), a large proportion of human immunodeficiency virus (HIV)-infected patients may develop moderate neurocognitive impairment. Antiretroviral drug passage into the central nervous system may be relevant for preventing and treating HIV-associated neurocognitive disorder; nevertheless, clear cerebrospinal fluid (CSF) p...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Antiviral therapy
دوره 16 6 شماره
صفحات -
تاریخ انتشار 2011